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SAY HELLO TO MY LITTLE FRIEND CIVIL RICO: THE THIRD
CIRCUIT GREEN LIGHTS INSURANCE SHAKEDOWN OF BIG
PHARMA WITH IN RE AVANDIA
MARIE BUSSEY-GARZA*
“[W]hatever [RICO’s] motives to begin with, we will end up with cases
involving all kinds of things not intended to be covered, and a
potpourri of language by which you can parade all kinds
of horrible examples of overreach.”
- Representative Abner J. Mivka1
I. CIVIL RICO: AN INTRODUCTION

TO A

FRIEND

OF

OURS

RICO—an acronym that traditionally struck fear in the criminal’s
heart—has, in recent years, morphed into the dread of every legitimate corporate defense attorney.2 Short for the Racketeer Influenced and Corrupt
* J.D. Candidate, 2017, Villanova University Charles Widger School of Law;
B.S. 2009, California State University, Fresno; B.B.A. 2002, The University of Texas
at Austin. I would like to thank (1) my husband, Abel Garza, for his love, support,
patience, encouragement, and editing assistance; (2) my parents, Debby and
Henry Bussey, for raising me to seek success while remembering not to take myself
too seriously; (3) my law review mentors—Melissa Ruth, Meghan Campbell, and
Matt Kaiser—for their support and encouragement; and (4) Melissa Ruth, Mark
Wilhelm, Brendan Hatfield, Allison Crowe, Rebecca Feuerhammer, Bob Turchick,
and Lauren Anthony for their editing feedback on this Casebrief.
Author’s Note: This Casebrief’s title was inspired by the classic mobster film
SCARFACE (Universal Pictures 1983). Some scholars claim the Racketeer
Influenced and Corrupt Organizations (RICO) Act was named after Enrico “Rico”
Bandello, the lead character in the 1938 classic Mafia film LITTLE CAESAR (Warner
Bros. 1931). See NATE HENDLEY, THE MAFIA: A GUIDE TO AN AMERICAN SUBCULTURE
161 (2013). In keeping with this Mafia–naming theme, the headings used
throughout this Casebrief employ Mafia slang. See GODMOTHER’S MAFIA
DICTIONARY, http://www.performancetwo.com/mobspeak.htm [https://perma.
cc/R8L2-MQL6] (last visited Oct. 13, 2016); AM. MAFIA, http://www.onewal.com/
maf-glos.html [https://perma.cc/95K6-ZM8G] (last visited Feb. 15, 2016).
1. 116 CONG. REC. 35204 (1970) (statement of Rep. Mikva) (discussing
implications of Organized Crime Control Act of 1970).
2. See Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C.
§§ 1961–68 (2012) (providing text of RICO); Sara E. Kropf, Civil RICO Class Actions: A New Bridge to the Courthouse?, 21 A.B.A. CLASS ACTION & DERIVATIVE SUITS

(625)
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Organizations Act, today’s RICO is a far cry from the law a notorious Boston mob boss once said “was only written for people like [him].”3 While
his comment succinctly and accurately describes RICO’s legislative intent—to combat mob activity—RICO today is most often used to target
legitimate businesses accused of so-called “garden variety” fraud.4
The Third Circuit recently considered one such civil RICO case: In re
Avandia Marketing, Sales Practices & Product Liability Litigation.5 In Avandia,
the Third Circuit held that a class of third-party payers (TPPs) had sufficiently alleged injury and causation within the meaning of RICO and
could proceed with a class action against a major pharmaceutical company
REP. 9, 9 (2011) (“Civil [RICO] class actions are one of the most significant litigation liabilities a modern corporation can face.”). For a discussion of reasons plaintiffs love—and defendants dread—civil RICO, see infra notes 30–37 and
accompanying text.
3. See Proposed RICO Reform Legislation: Hearing on S. 1523 Before the S. Comm. on
the Judiciary, 100th Cong. 35 (1989) (statement of William F. Feld, Assistant Attorney General, Criminal Division) (emphasis added) (quoting Gennaro Angiulo, former Boston mob underboss). American Mafia figure Gennaro Angiulo reportedly
made this statement to other members of his crime family while being surveilled by
the Federal Bureau of Investigations. See id.; see also Sedima, S.P.R.L. v. Imrex Co.,
473 U.S. 479, 500 (1985) (“We nonetheless recognize that, in its private civil version, RICO is evolving into something quite different from the original conception
of its enactors.”); PAUL BATISTA, CIVIL RICO PRACTICE MANUAL § 2.04[G] (2d ed.
2015) (“[I]f the clarity (and bias) of the Hruska–McClellan themes had prevailed,
banks, securities firms, accountants, and the corporate managers of today’s world
would never have had any real concern about RICO.”); William Rehnquist, Get
RICO Cases out of My Courtroom, WALL ST. J., May 19, 1989, at A14, available at ProQuest Central, Document No. 398092521 (“[C]ivil RICO is now being used in ways
that Congress never intended.”).
4. See Sedima, 473 U.S. at 526 (Powell, J., dissenting) (“[RICO] has been used
more often against respected businesses with no ties to organized crime, than
against the mobsters who were the clearly intended target of the statute.”); see also
JONATHAN SHELDON, FEDERAL DECEPTION LAW § 7.1.5, at 139–40 (1st ed. 2012)
(“[C]ivil RICO has been used far more often against ‘legitimate’ businesses than
against ‘the archetypal, intimidating gangster.’ ” (quoting Sedima, 473 U.S. at
499)); Lee Coppola & Nicholas DeMarco, Civil RICO: How Ambiguity Allowed the
Racketeer Influenced and Corrupt Organizations Act to Expand Beyond Its Intended Purpose, 38 NEW ENG. J. ON CRIM. & CIV. CONFINEMENT 241, 254 (2012) (“RICO is
rarely used in today’s world against the traditional enemy that Congress sought to
eradicate by its enactment, the American Mafia.”); John M. Nonna & Melissa P.
Corrado, RICO Reform: “Weeding out” Garden Variety Disputes Under the Racketeer Influenced and Corrupt Organizations Act, 64 ST. JOHN’S L. REV. 825, 825 (1990) (citation
omitted) (discussing RICO reform efforts to “curtail[ ] the statute as a weapon in
‘garden variety’ lawsuits against legitimate businesses”); Pamela Bucy Pierson,
RICO Trends: From Gangsters to Class Actions, 65 S.C. L. REV. 213, 215 (2013) (“Criminal RICO’s time has come and gone; civil RICO’s time has not yet arrived.”). The
term “garden variety” is often used to describe traditional state fraud claims. See,
e.g., Rehnquist, supra note 3 (noting most “civil suits filed under [civil RICO] have
nothing to do with organized crime” but rather “are garden–variety civil fraud
cases of the type traditionally litigated in state courts”). For a discussion of RICO’s
legislative intent, see infra notes 12–19 and accompanying text.
5. 804 F.3d 633 (3d Cir. 2015), cert. denied sub nom. GlaxoSmithKline LLC v.
Allied Servs. Div. Welfare Fund, 136 S. Ct. 2409 (2016).
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accused of fraud.6 This Casebrief asserts that Avandia aligns with the modern trend of shifting RICO away from targeting organized crime, but the
opinion departs significantly from the Third Circuit’s own precedent.7
Part II examines RICO’s evolution from a law targeting the Italian-American Mafia into something much broader, focusing particularly on recent
claims by TPPs against drug manufacturers.8 Parts III and IV discuss and
critique the Avandia decision, highlighting the court’s divergence from its
own prior precedent.9 Part V offers practical guidance for practitioners,
cautioning plaintiff’s counsel to employ restraint and urging defense attorneys to call for legislative reform.10 Finally, Part VI briefly considers the
big-picture implications of Avandia.11
II. CRIMINAL BACKGROUND CHECK: RICO’S PAST
Congress enacted RICO as Title IX of the Organized Crime Control
Act of 1970 for the purpose of “eradicat[ing] organized crime.”12 To that
end, RICO created “new remedies to deal with the unlawful activities of
those engaged in organized crime.”13 One such new remedy was a private
civil right of action, available to “[a]ny person injured in his business or
property by reason of a [RICO violation].”14 Virtually ignored in the dec6. See id. at 645 (“We conclude therefore that plaintiffs’ alleged injury is sufficiently direct to satisfy the RICO proximate cause requirement at this stage.”). For
a discussion and critique of the Avandia decision, see infra notes 100–38 and accompanying text.
7. See infra notes 29–42 and accompanying text for a discussion of civil
RICO’s evolution from a weapon against organized crime into a much broader
statute. See infra notes 100–38 and accompanying text for a discussion of the
Third Circuit’s divergence from prior precedent in Avandia.
8. See infra notes 12–99 and accompanying text for a discussion of RICO’s
legislative and judicial history.
9. See infra notes 100–38 and accompanying text for an analysis of the Third
Circuit’s Avandia decision.
10. See infra notes 140–78 and accompanying text for a discussion of the
Avandia decision’s practical implications for practitioners.
11. See infra notes 179–82 and accompanying text for a discussion of the
far–reaching implications of Avandia.
12. See Pub. L. No. 91–452, 84 Stat. 922, 922–23 (1970) (codified at 18 U.S.C.
§§ 1961–68 (2012)) (emphasis added) (describing impetus for and purpose of
act); REPORT OF THE AD HOC CIVIL RICO TASK FORCE OF THE ABA SECTION OF
CORPORATION, BANKING AND BUSINESS LAW 70 (1985) [hereinafter ABA REPORT]
(discussing intent of RICO to target organized crime). For further discussion of
the legislative history of civil RICO, see infra notes 17–22 and accompanying text.
13. See 84 Stat. at 923 (emphasis added) (describing new “legal tools” for combatting organized crime); see also Sedima, S.P.R.L. v. Imrex Co., 473 U.S. 479, 498
(1985) (“RICO was an aggressive initiative to . . . develop new methods for fighting
crime.”); G. Robert Blakey & Brian Gettings, Racketeer Influenced and Corrupt Organizations (RICO): Basic Concepts—Criminal and Civil Remedies, 53 TEMP. L.Q. 1009,
1013 (1980) (“RICO was the end product of a long process of legislative effort to
develop new legal remedies to deal with an old problem: ‘organized crime.’ ”). For
a discussion of Congress’s intent in creating RICO, see infra notes 17–22 and accompanying text.
14. See 18 U.S.C. § 1964(c) (defining private civil right of action).
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ade after its enactment, civil RICO gained popularity with plaintiffs in the
1980s, and its scope and use have continued to expand ever since.15 With
that expansion, courts have struggled to define the meaning and limits of
RICO’s language.16
A.

Goodbye Golden Age, Hello RICO: Purpose and Text

Congress’s expressed purpose in enacting RICO was to keep organized crime from infiltrating legitimate businesses.17 This unprecedented
law resulted from decades of congressional research on organized crime
that identified such infiltration as a widespread problem.18 Congress’s research culminated in the 1967 Katzenbach Commission Report, which defined organized crime as a national crime syndicate comprised mostly of
Italian-American men and known as “the Mafia” or “La Cosa Nostra.”19
In drafting legislation, however, Congress realized a law targeting a
specific ethnic group would not pass constitutional muster.20 Conse15. See infra notes 29–42 and accompanying text for a discussion of the increasing scope of civil RICO.
16. See infra notes 43–138 and accompanying text for a discussion of judicial
struggles to apply civil RICO.
17. See 84 Stat. at 922–23 (explaining need to target widespread and
highly–sophisticated organized crime that was “increasingly used to infiltrate and
corrupt legitimate business” in America); United States v. Turkette, 452 U.S. 576,
591 (1981) (“[T]he major purpose of [RICO] is to address the infiltration of legitimate business by organized crime.”); BATISTA, supra note 3, § 2.04 (describing
RICO’s purpose); ABA REPORT, supra note 12, at 70 (“Congress’ principal aim in
enacting RICO in 1970 was to thwart the infiltration of organized crime into legitimate business.”); Blakey & Gettings, supra note 13, at 1014–15 (describing RICO’s
legislative history).
18. See PRESIDENT’S COMMISSION ON LAW ENFORCEMENT AND ADMINISTRATION
OF JUSTICE, THE CHALLENGE OF CRIME IN A FREE SOCIETY 192 (1967) [hereinafter
KATZENBACH REPORT] (describing results of congressional research on organized
crime); BATISTA, supra note 3, § 2.04 (describing legislative history of RICO);
Blakey & Gettings, supra note 13, at 1014–15 (describing same). While committee
reports dating back to the 1950s served as a backdrop for the Organized Crime
Control Act of 1970, the Katzenbach Report served as the direct impetus for enactment of the new law. See BATISTA, supra note 3, § 2.04. As early as 1951, the
Kefauver Committee—“the first modern group to study organized crime in a systematic fashion”—reported to the Senate that organized crime was systematically
infiltrating legitimate business enterprises. See id. By 1960, the McClellan Committee had added to the developing body of knowledge on organized crime—identifying the Italian Mafia, or La Cosa Nostra, as the national organized crime syndicate
infiltrating both legitimate businesses and labor unions. See Blakey & Gettings,
supra note 13, at 1014–15 (detailing investigation that “exposed the structure of
the national syndicate of organized crime known as the Mafia or La Cosa Nostra”).
19. See KATZENBACH REPORT, supra note 18, at 192 (describing organized
crime in America). The Katzenbach Report defined organized crime as a nationwide criminal organization whose “membership [was] exclusively Italian.” See id.
The Report also “indicate[d] that the organization as a whole [had] changed its
name from the Mafia to La Cosa Nostra.” Id.
20. See Sedima, S.P.R.L. v. Imrex Co., 473 U.S. 479, 525 (1985) (Powell, J.,
dissenting) (“The legislative history reveals that Congress did not state explicitly
that the statute would reach only members of the Mafia because it believed there
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quently, Congress enacted legislation explicitly aimed at organized crime
that never actually defines “organized crime.”21 Rather, Congress employed broad language that critics lament as “notoriously ambiguous.”22
Although RICO is primarily a criminal statute, the law also creates a
civil remedy enforceable by either the government or a private party.23
This civil remedy mandates treble damages and attorney’s fees for a successful plaintiff.24 Under RICO’s broad language, “any person” can bring
a civil RICO claim in federal court by showing (1) a business injury
(2) caused “by reason of” (3) a RICO violation.25
The statute defines a RICO violation as investing, acquiring an interest in, or conducting the affairs of an enterprise “through a pattern of
racketeering activity.”26 “Racketeering activity,” in turn, is defined as “any
were constitutional problems with establishing such a specific status offense.” (citing 116 CONG. REC. 35343–44 (remarks of Rep. Celler); id. at 35344 (remarks of
Rep. Poff))); DOUGLAS E. ABRAMS, THE LAW OF CIVIL RICO § 1.1, at 10 (1991)
(“[A]n express organized crime prohibition might have led courts to strike down
RICO for creating an unconstitutional status offense.” (footnote omitted));
BATISTA, supra note 3, § 2.04[G] (explaining constitutional problems with “identifying specific crime families by national origin”); ABA REPORT, supra note 12, at 71
(“[T]o ensure the constitutionality of the statute, Congress made the central proscription of the statute the use of a ‘pattern of racketeering activities’ in connection with an ‘enterprise,’ rather than merely outlawing membership in the Mafia,
La Cosa Nostra, or other organized criminal syndicates.”).
21. See 18 U.S.C. §§ 1961–68 (2012) (lacking definition of organized crime);
see also BATISTA, supra note 3, § 2.04 (explaining reasons for omitting definition of
organized crime). For further discussion on the impetus for omitting a definition
of organized crime, see supra note 20 and accompanying text.
22. See BATISTA, supra note 3, § 1.02 (discussing broad language of RICO); see
also Coppola & DeMarco, supra note 4, at 241 (“One of the principal reasons for
the unforeseen and unprecedented expansion of RICO, especially in civil cases, is
the broad and ambiguous language of the statute.”).
23. See 18 U.S.C. § 1964 (describing civil remedy). Section 1964(b) provides
that “[t]he Attorney General may institute proceedings under this section.” Id.
§ 1964(b). Section 1964(c) provides that “[a]ny person injured in his business or
property by reason of a violation of [S]ection 1962 of this chapter may sue therefor
in any appropriate United States district court and shall recover threefold the damages he sustains and the cost of the suit, including a reasonable attorney’s fee.” Id.
§ 1964(c).
24. See id. § 1964(c) (mandating treble damages and attorney’s fees).
25. See id. (defining civil cause of action).
26. See id. § 1962 (defining RICO violation). Section 1962(a) makes it “unlawful for any person who has received any income derived . . . from a pattern of
racketeering activity . . . to use or invest . . . such income . . . in acquisition of any
interest in, or the establishment or operation of, any enterprise” engaged in interstate or foreign commerce. See id. § 1962(a). Section 1962(b) makes it “unlawful
for any person through a pattern of racketeering activity . . . to acquire or maintain, directly or indirectly, any interest in or control of any enterprise which is
engaged in, or the activities of which affect, interstate or foreign commerce.” See
id. § 1962(b). Section 1962(c) makes it “unlawful for any person employed by or
associated with any enterprise engaged in, or the activities of which affect, interstate or foreign commerce, to conduct or participate, directly or indirectly, in the
conduct of such enterprise’s affairs through a pattern of racketeering activity.” Id.
§ 1962(c). Section 1962(d) makes it “unlawful for any person to conspire to vio-
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act which is indictable under” a long list of state and federal crimes, including the catch-all provisions for mail and wire fraud.27 Additionally,
RICO broadly defines a “pattern of racketeering activity” as “at least two
acts of racketeering activity” within a ten-year period.28
B.

A Made Man: The Rise of Civil RICO

After a decade of dormancy, RICO emerged in the 1980s as “the
weapon of choice for civil plaintiffs who perceived [its] broad language
[as] a means for articulating novel or creative claims.”29 Besides its malleable language, civil RICO attracts private plaintiffs for three key reasons:
(1) mandatory treble damages and attorney’s fees; (2) access to federal
courts; and (3) broad judicial discretion.30
First and foremost, the statute mandates treble damages and attorney’s fees for the successful plaintiff.31 This risk of high-stakes damages
late any of the provisions of subsection (a), (b), or (c) of this section.” Id.
§ 1962(d).
27. See id. § 1961(1) (listing RICO predicate acts). Section 1961(1)(A) defines “racketeering activity” as “any act or threat involving murder, kidnapping,
gambling, arson, robbery, bribery, extortion, dealing in obscene matter, or dealing
in a controlled substance.” Id. § 1961(1)(A). Section 1961(1)(B) further defines
“racketeering activity” as “any act which is indictable under any of the following
provisions of [T]itle 18, United States Code: . . .” Id. § 1961(1)(B). The statute
then lists more than one hundred sections of the United States Code. See id. Despite this long list of predicate acts, “only a few of the specifically designated offenses have gained a dominant role in actual civil litigations” such as “mail fraud
[and] wire fraud.” See BATISTA, supra note 3, § 2.02.
28. See 18 U.S.C. § 1961(5) (stating that “ ‘pattern of racketeering activity’ requires at least two acts of racketeering activity, one of which occurred after the
effective date of this chapter and the last of which occurred within ten years (excluding any period of imprisonment) after the commission of a prior act of racketeering activity”).
29. See BATISTA, supra note 3, § 1.01 (describing civil RICO’s emergence in
1980s, “tentatively” at first “and then, by 1985, in a torrent that has not abated over
the last several decades”); see also ABRAMS, supra note 20, § 1.1, at 5 (“Civil RICO
went virtually unnoticed for a decade.” (footnote omitted)); Nonna & Corrado,
supra note 4, at 825 (“In the early 1980’s, the plaintiffs’ bar began to use RICO as a
weapon ‘against defendants who carried portfolios instead of pistols.’ ” (quoting
Martha Bridegam, Business Targets Aim Back at Racketeering Law, 45 CONG. Q. WKLY.
REP. 2130, 2130 (1987))); Rehnquist, supra note 3 (discussing widespread use of
civil RICO in 1980s for state fraud claims).
30. See infra notes 31–37 and accompanying text for a discussion of RICO’s
plaintiff–friendly qualities.
31. See 18 U.S.C. § 1964(c) (“Any person injured in his business or property
by reason of a violation of section 1962 . . . shall recover threefold the damages he
sustains and the cost of the suit, including a reasonable attorney’s fee . . . .”).
According to former Justice Thurgood Marshall, “private litigants . . . lured by the
prospect of treble damages and attorney’s fees, have a strong incentive to invoke
RICO’s provisions.” See Sedima, S.P.R.L. v. Imrex Co., 473 U.S. 479, 504 (1985)
(Marshall, J., dissenting). Additionally, former Chief Justice William Rehnquist explained, “RICO’s treble damages provisions create a powerful incentive for attorneys to attempt to bring facts traditionally thought to establish other causes of
action within the ambit of the statute.” Rehnquist, supra note 3.
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creates what one RICO scholar terms an “in terrorem effect,” ironically arming plaintiffs for mob-like, strong-arm tactics.32 Not surprisingly, the
threat of treble damages causes most civil RICO claims to settle before
trial.33 Second, RICO permits private plaintiffs to bring suit in federal
court.34 Thus, a plaintiff with a mere garden variety state fraud claim may
gain access to the federal courts by demonstrating the alleged fraud occurred on at least two occasions within a ten-year period and involved at
least one of the many predicate acts enumerated in the statute.35 Third,
the statute grants federal courts broad discretion to “prevent and restrain”
RICO violations.36 This broad discretion permits the court to restrict the
activities of an enterprise or even order its dissolution, which could effectively put a successful plaintiff’s competitor out of business.37
The expansive use of civil RICO in the 1980s elicited calls for legislative reform from scholars concerned about misuse and abuse.38 Ever re32. See BATISTA, supra note 3, § 1.02 (describing RICO’s in terrorem effect).
Batista describes civil RICO’s in terrorem effect, noting “RICO became the weapon
of choice for civil plaintiffs who perceived . . . a means for . . . escalating the
potential for the litigation equivalent of terror—the availability of treble damages.”
See id. § 1.01; see also Pelletier v. Zweifel, 921 F.2d 1465, 1522 (11th Cir. 1991)
(“When used improperly . . . [civil RICO] allow[s] a complainant to shake down his
opponent and, given the expense of defending a RICO charge, to extort a settlement.” (emphasis added)).
33. See BATISTA, supra note 3, § 1.02 (discussing risks to defendants of civil
RICO litigation). According to Batista, “[t]he vast majority of civil RICO battles
are waged and concluded at the pretrial stage . . . since the risks of full litigation
are often perceived as too great.” Id. Justice Marshall also acknowledged this concern in his Sedima dissent, explaining “the [civil RICO] defendant, facing a tremendous financial exposure in addition to the threat of being labeled a
‘racketeer,’ will have a strong interest in settling the dispute.” See Sedima, 473 U.S.
at 504 (Marshall, J., dissenting).
34. See 18 U.S.C. § 1964(c) (“Any person injured in his business or property
by reason of a violation of section 1962 of this chapter may sue therefor in any
appropriate United States district court . . . .”); see also Coppola & DeMarco, supra
note 4, at 253 (“Because of the Court’s expanding interpretation of civil RICO,
private litigants have been lured by the prospect of treble damages and a federal
courtroom.” (emphasis added)). Former Chief Justice William Rehnquist explained,
“if treble damages are available in federal court, but not in state court, the cases
will gravitate to the former.” See Rehnquist, supra note 3.
35. See supra notes 25–28 and accompanying text for a discussion of the statute’s requirements.
36. See 18 U.S.C. § 1964(a) (granting courts broad discretion). Section
1964(a) gives “district courts of the United States . . . jurisdiction to prevent and
restrain violations of section 1962 of [RICO] by issuing appropriate orders.” Id.
The statute defines appropriate orders as “including, but not limited to: ordering
any person to divest himself of any interest, direct or indirect, in any enterprise;
imposing reasonable restrictions on the future activities or investments of any person; . . . or ordering dissolution or reorganization of any enterprise.” Id.
37. See id. (granting courts broad powers to enforce RICO).
38. See BATISTA, supra note 3, § 2.10 (noting “decades of lobbyist and other
opposition” to civil RICO); ABA REPORT, supra note 12, at 1 (calling for legislative
reform of civil RICO); William J. Hughes, RICO Reform: How Much Is Needed?, 43
VAND. L. REV. 639, 640 (1990) (describing congressional discussions of RICO reform). In its Summary of Recommendations, the ABA Task Force on civil RICO
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luctant to appear soft on crime, Congress has enacted only one substantial
civil RICO reform to date—the “elimination of securities fraud as a predicate act.”39 In the absence of legislative reform, many critics have called
for use of Rule 11 of the Federal Rules of Civil Procedure to deter civil
RICO abuse.40 Rule 11 grants federal judges broad discretion to sanction
attorneys and law firms for bringing frivolous claims.41 Despite these critireform described “a demonstrated need for legislative amendment of the private
civil treble damages provision” of RICO. See ABA REPORT, supra note 12, at 1. According to the Task Force, civil RICO’s application was “grossly overbroad, encompassing business transactions that could not have been foreseen or intended by
Congress.” See id. According to Congressman Hughes, “prominent organizations
that have petitioned Congress to amend civil RICO” include “the American Bar
Association, National Association of Manufacturers, American Civil Liberties
Union, United States Chamber of Commerce, AFL–CIO, American Institute of
Certified Public Accountants, Securities Industry Association,” and many others.
See Hughes, supra note 38, at 640.
39. See BATISTA, supra note 3, § 2.10 (describing elimination of predicate offense of securities fraud as “only substantive amendment to RICO even after decades of lobbyist and other opposition”); Douglas E. Abrams, Crime Legislation and
the Public Interest: Lessons from Civil RICO, 50 SMU L. REV. 33, 76 (1996) (explaining
difficulty of reforming civil RICO because “[c]orrection . . . [is] politically unpalatable because only the hardiest legislators care to risk appearing ‘soft on crime’ ”);
Stephan E. Oestreicher, Scheidler Meets Morrison (at the Entrance to a Health Clinic),
35 CREIGHTON L. REV. 693, 718 (2002) (attributing failure of annual efforts to reform civil RICO to congressional fear of looking “soft on crime”).
40. See Adam H. Bloomenstein, Developing Standards for the Imposition of Sanctions Under Rule 11 of the Federal Rules of Civil Procedure, 21 AKRON L. REV. 289,
307–08 (1998) (suggesting that “filing of frivolous RICO claims deserves a heightened sense of scrutiny under Rule 11”); Petra J. Rodrigues, The Civil RICO Racket:
Fighting Back with Federal Rule of Civil Procedure 11, 64 ST. JOHN’S L. REV. 931, 949–51
(1990) (encouraging courts to utilize Rule 11 sanctions to deter civil RICO abuse);
Nicholas L. Nybo, Note, A Three–Ring Circus: The Exploitation of Civil Rico, How Treble
Damages Caused It, and Whether Rule 11 Can Remedy the Abuse, 18 ROGER WILLIAMS U.
L. REV. 19, 35–51 (2013) (describing “deterrence under Rule 11” and encouraging
courts to “levy harsh [Rule 11] sanctions against fraudulent RICO claimants”); see
also Curtis & Assocs. v. Law Offices of David M. Bushman, Esq., 758 F. Supp. 2d
153, 183 (E.D.N.Y. 2010) (warning “plaintiffs that further efforts to convert garden–variety pleadings and litigation correspondence into racketeering
acts . . . may leave the court with no choice but to impose [Rule 11] sanctions”);
Katzman v. Victoria’s Secret Catalogue, 167 F.R.D. 649, 660 (S.D.N.Y. 1996) (“Rule
11’s deterrence value is particularly important in the RICO context, as the commencement of a civil RICO action has ‘an almost inevitable stigmatizing effect’ on
those named as defendants.” (quoting Figueroa Ruiz v. Alegria, 896 F.2d 645, 650
(1st Cir. 1990))); Asbeka Indus. v. Travelers Indem. Co., 831 F. Supp. 74, 90–91
(E.D.N.Y. 1993) (“To stem the rising tide of RICO suits commenced without
thoughtful attention to fundamental principles attendant upon that cause of action, the imposition of Rule 11 sanctions may serve the salutary purpose of discouraging such thoughtless litigation . . . .”).
41. See FED. R. CIV. P. 11 (“If . . . the court determines that Rule 11(b) has
been violated, the court may impose an appropriate sanction on any attorney, law
firm, or party that violated the rule . . . .”). Under Rule 11(b), an attorney must
certify that a pleading “is not being presented for any improper purpose, such as
to harass, cause unnecessary delay, or needlessly increase the cost of litigation” and
that “the claims, defenses, and other legal contentions are warranted by existing
law or by a nonfrivolous argument for extending . . . law.” See id. Rule 11(c) grants
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cisms and some imposition of Rule 11 sanctions, civil RICO’s use and
scope have continued to grow.42
C.

Supreme Court Beefs: High Court Struggles with RICO

During congressional debates, one congressman astutely predicted
that RICO would “subject the courts . . . to incredible burdens and
problems in trying to decipher, administer, and uphold [its] provisions.”43
Not surprisingly, courts have struggled to decipher, among other things,
whether civil RICO requires a prior criminal conviction, whether a separate racketeering injury is needed, how to define “enterprise,” how to measure the duration and accrual of the statute of limitations, whether an
economic motive is required, and whether but-for or proximate cause is
needed.44 In general, the Supreme Court has consistently taken an exthe court broad discretion to “impose an appropriate sanction on any attorney, law
firm, or party that violated [Rule 11(b)].” See id. The court may issue sanctions
sua sponte or on motion from opposing counsel. See id.
42. See, e.g., Avirgan v. Hull, 932 F.2d 1572 (11th Cir. 1991) (imposing sanctions in excess of one million dollars for RICO claims brought by journalists claiming injury from bombing allegedly caused by racketeering activity of CIA
operatives, military personnel, and mercenaries); Pelletier v. Zweifel, 921 F.2d
1465 (11th Cir. 1991) (imposing sanctions in RICO action brought against attorney); Ryan v. Clemente, 901 F.2d 177 (1st Cir. 1990) (imposing sanctions against
plaintiff’s attorney in RICO action alleging state officials failed to investigate police
examination cheating scandal); O’Malley v. N.Y.C. Transit Auth., 896 F.2d 704 (2d
Cir. 1990) (imposing sanctions in frivolous RICO claim brought by former employee against former employer); Fred A. Smith Lumber Co. v. Edidin, 845 F.2d
750 (7th Cir. 1988) (imposing sanctions against plaintiff’s attorney in RICO claim
over construction dispute); Drobny v. JP Morgan Chase Bank, 929 F. Supp. 2d 839
(N.D. Ill. 2013) (reminding plaintiffs of “the strictures of Rule 11”); Curtis & Assocs., 758 F. Supp. 2d at 182 (warning plaintiffs of possible Rule 11 sanctions);
Katzman, 167 F.R.D. at 653, 659–61 (imposing sanctions against attorneys of plaintiffs alleging Victoria’s Secret’s “pricing structures with respect to catalogues
mailed to different recipients constitute[d] a [RICO] violation”); Binghamton Masonic Temple, Inc. v. Bares, 168 F.R.D. 121, 127 (N.D.N.Y. 1996) (imposing sanctions in civil RICO action brought against non–profit by former president); Asbeka,
831 F. Supp. at 88–91 (E.D.N.Y. 1993) (imposing sanctions in RICO action
brought by insureds against insurers). For a discussion of civil RICO’s explosive
growth beginning in the 1980s, see supra note 29 and accompanying text.
43. See 116 CONG. REC. 35,205 (1970) (statement of Rep. Mikva) (discussing
implications of Organized Crime Control Act of 1970).
44. See, e.g., Hemi Grp., LLC v. City of New York, 559 U.S. 1 (2010) (addressing proximate cause); Boyle v. United States, 556 U.S. 938 (2009) (addressing definition of enterprise); Bridge v. Phoenix Bond & Indem. Co., 553 U.S. 639 (2008)
(rejecting first–party reliance requirement); Anza v. Ideal Steel Supply Corp., 547
U.S. 451 (2006) (addressing proximate cause); Cedric Kushner Promotions, Ltd. v.
King, 533 U.S. 158 (2001) (discussing definition of enterprise); Rotella v. Wood,
528 U.S. 549 (2000) (eliminating injury and pattern discovery rule for determining
accrual of statute of limitations); Klehr v. A.O. Smith Corp., 521 U.S. 179 (1997)
(eliminating last predicate act rule for determining accrual of statute of limitations); Nat’l Org. for Women v. Scheidler, 510 U.S. 249 (1994) (rejecting economic motive requirement); Holmes v. Sec. Inv’r Prot. Corp., 503 U.S. 258 (1992)
(establishing proximate cause requirement); Agency Holding Corp. v. Malley–Duff
& Assocs., 483 U.S. 143 (1987) (establishing four–year statute of limitations but
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pansive view of civil RICO, while lower courts have sought to limit RICO’s
use.45
Although the Supreme Court has generally construed civil RICO liberally, the Court has taken a more constricted view of causation, and lower
courts have especially struggled with this elusive element.46 Between 1992
and 2010, the High Court considered civil RICO causation four times and
found causation lacking all but once.47 In Holmes v. Securities Investor Protection Corp.,48 the first in this line of cases, the Supreme Court considered
the meaning of RICO’s requirement that an injury occur “by reason of” a
RICO violation.49 The Court acknowledged that a literal reading would
require only but-for causation, but rejected this interpretation and concluded that Congress intended to require proximate cause.50
not reaching issue of accrual); Sedima, S.P.R.L. v. Imrex Co., 473 U.S. 479 (1985)
(rejecting requirement of prior criminal conviction or separate racketeering
injury).
45. See BATISTA, supra note 3, § 2.05[T] (describing “the Supreme Court’s
generally expansive and liberal interpretation of the civil applications of RICO and
the lower courts’ consistent efforts to develop narrow applications of the statute”);
SHELDON, supra note 4, § 7.1.5, at 139 (“[T]he Supreme Court has rebuffed several
lower court efforts to limit [civil RICO’s] scope, supporting an expansive construction.” (citing Sedima, 473 U.S. at 497–99; United States v. Turkette, 452 U.S. 576,
586–87 (1981))). Despite acknowledging that civil RICO’s use has stretched beyond its original intent, the Supreme Court has been hesitant to constrict the statute, pointing to the statute’s explicit call for a liberal construction. See, e.g., Sedima,
473 U.S. at 498–500 (“RICO is to ‘be liberally construed to effectuate its remedial
purposes.’ ” (quoting Organized Crime Control Act of 1970, Pub. L. 91–452,
§ 904(a), 84 Stat. 922, 947 (1970))). The divergent approaches of the Supreme
Court and lower courts are exemplified by Sedima, the seminal civil RICO decision
in which the Court rejected the lower court’s requirements of a prior conviction
and separate racketeering injury. See id. at 522. Sedima involved a civil RICO dispute between two joint venturers, one of whom accused the other of fraud. See id.
at 483–84. The lower court dismissed the case because the defendant had not
been criminally convicted of any predicate act, and the plaintiff alleged only a
traditional fraud injury. See id. at 484–85. The Supreme Court reversed, finding
that neither a prior criminal conviction nor a separate “racketeering injury” was
needed. See id. at 522. Despite acknowledging “concern over the consequences of
an unbridled reading of the statute,” the Supreme Court rejected the limitations
and has consistently taken a liberal approach ever since. See id. at 481.
46. See infra notes 47–138 and accompanying text for a discussion of civil
RICO’s causation element.
47. See infra notes 48–67 and accompanying text for a discussion of Supreme
Court cases on RICO causation.
48. 503 U.S. 258 (1992).
49. See id. at 265–66 (interpreting “by reason of”).
50. See id. (interpreting RICO’s causation element). The Court acknowledged that, under a plain reading of the civil RICO statute, a plaintiff could recover “simply on showing that the defendant violated § 1962, the plaintiff was
injured, and the defendant’s violation was a ‘but for’ cause of plaintiff’s injury,”
but rejected “[t]his construction [as] hardly compelled.” See id. Rather, the Court
noted, “Congress modeled § 1964(c) on . . . § 4 of the Clayton Act,” and “Congress
enacted § 4 in 1914 with language borrowed from § 7 of the Sherman Act,” which
undoubtedly incorporated the common law principle of proximate causation. See
id. at 267–68. The Court explained that “[b]efore 1914, lower federal courts had
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In Holmes, the defendant defrauded several broker-dealers and caused
their insolvency, which in turn caused the broker-dealers’ customers to
incur losses.51 The broker-dealers’ insurer alleged injury from paying the
customers’ claims.52 The Court found proximate cause lacking because
the defendant’s fraud against a third party (the broker-dealers) was not
the direct cause of the plaintiff-insurer’s injury.53 The Court reasoned the
fraud directly caused the broker-dealers’ failure, but only indirectly caused
the insurer’s losses.54 As it did in Holmes, the Court typically bars recovery
where the plaintiff’s injury results from fraud on a third party.55
In two similar cases, Anza v. Ideal Steel Supply Corp.56 and Hemi Group,
LLC v. City of New York,57 the Court found proximate cause lacking because at least one step separated the fraudulent conduct from the conduct
that directly caused the injuries.58 In Anza, the plaintiff-business alleged
injury from a competitor that kept prices low by fraudulently withholding
tax payments from the state.59 The Court concluded the plaintiff’s injury
read § 7 [of the Sherman Act] to incorporate common–law principles of proximate causation.” See id. at 267. Therefore, the Court concluded, because Congress
“used the same words” as it had in the Clayton and Sherman Acts, it was appropriate to “assume [Congress] intended them to have the same meaning that courts
had already given them.” See id. at 268. The Court explicitly held that
“[p]roximate cause is thus required.” See id.
51. See id. at 261–63 (discussing facts of case). Holmes involved a stock manipulation scheme, which directly caused several broker–dealers to become unable to
satisfy financial obligations to their customers. See id. at 262–63. The broker–dealers were members of the Securities Investor Protection Corporation
(SIPC), a non–profit organization that exists to protect the interests of the customers of SIPC’s member broker–dealers. See id. at 261–62. In carrying out its role,
SIPC advanced $13 million to cover claims asserted by the broker–dealers’ customers. See id. at 263. Subsequently, SIPC brought a civil RICO claim against the alleged stock manipulator. See id. at 262–63.
52. See id. at 261, 263 (“Respondent Securities Investor Protection Corporation (SIPC) [insurer] alleges that petitioner Robert G. Holmes, Jr., conspired in a
stock–manipulation scheme that disabled two broker–dealers from meeting obligations to customers, thus triggering SIPC’s statutory duty to advance funds to reimburse the customers.”).
53. See id. at 271 (“[T]he link is too remote between the stock manipulation
scheme alleged and the customers’ harm, being purely contingent on the harm
suffered by the broker–dealers.”).
54. See id. (“[T]he conspirators have allegedly injured these customers only
insofar as the stock manipulation first injured the broker–dealers.”).
55. See infra notes 56–62 and accompanying text for a discussion of
post–Holmes jurisprudence barring recovery in cases involving fraud on a third
party.
56. 547 U.S. 451 (2006).
57. 559 U.S. 1 (2010).
58. See infra notes 59–62 and accompanying text for a discussion of Anza and
Hemi Grp.
59. See Anza, 547 U.S. at 453–55 (discussing plaintiff’s claims). In Anza, a mill
company with locations in Queens and the Bronx brought a RICO claim against a
competing business. See id. at 453–54. The plaintiff alleged the competitor had
defrauded the government by failing to remit sales tax from cash–paying customers and had committed mail and wire fraud by submitting fraudulent tax returns to
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was not sufficiently direct because it resulted from the defendant’s decision to offer lower prices, an act “distinct from the alleged RICO violation
(defrauding the State).”60 Similarly, in Hemi Group, the city of New York
alleged financial harm when an out-of-state cigarette vendor failed to file a
required report listing sales to New York State customers.61 The Court
found proximate cause lacking, noting “the [c]ity’s harm was directly
caused by the [customers’]” failure to pay taxes to the city, not by the
defendant’s failure to file the report with the state.62
conceal the illegal conduct. See id. at 454. According to the plaintiff, the competitor kept prices low through this fraudulent scheme and used the fraudulently-obtained excess revenue to open a Bronx location. See id. at 455. The plaintiff
alleged financial harm as a result of the competitor’s ability to acquire a significant
percent of plaintiff’s market share with these low prices and new location. See id.
60. See id. at 458 (explaining holding and reasoning). Notably, the Second
Circuit had held that where a complaint alleges “that the defendant engaged in a
pattern of fraudulent conduct that is within the RICO definition of racketeering
activity and that was intended to and did give the defendant a competitive advantage over the plaintiff, the complaint adequately pleads proximate cause.” See
Ideal Steel Supply Corp. v. Anza, 373 F.3d 251, 263 (2d Cir. 2004). The Second
Circuit further concluded that such a pleading was adequate “even where the
scheme depended on fraudulent communications directed to and relied on by a
third party rather than the plaintiff.” See id. The Supreme Court disagreed, finding proximate cause lacking because “[t]he direct victim of [the defendant’s fraudulent] conduct was the State of New York,” not the plaintiff, and the alleged injury
resulted from the defendant’s decision to offer lower prices, an act “entirely distinct from the alleged RICO violation (defrauding the State).” See Anza, 547 U.S.
at 458. The Court explained its conclusion could be “confirmed by considering
the directness requirement’s underlying premises.” See id. Specifically, the Court
noted the difficulty of assessing damages and the risk of duplicative recoveries increase with the remoteness of an injury. See id. at 458–60 (explaining Court’s reasoning). In Anza, the Court reasoned, “[b]usinesses lose and gain customers for
many reasons,” multiple factors other than the defendant’s fraudulent activity
could have contributed to the plaintiff’s lost sales, and it would be difficult to determine what portion of the loss was due to the fraudulent scheme. See id. at 459
(discussing remoteness of injury). Additionally, the Court noted, the state was better–suited to recover because it would be relatively simple to determine the
amount of tax revenue the defendant had fraudulently withheld. See id. at 460
(explaining reasoning).
61. See Hemi Grp., 559 U.S. at 4 (describing facts). The court explained,
“[t]he City of New York taxes the possession of cigarettes.” See id. Out–of–state
vendors may sell cigarettes to New York City residents, and “[n]either state nor city
law requires [the out–of–state vendors] to charge, collect, or remit the [New York
City] tax.” See id. “Federal law, however, requires out–of–state vendors . . . to submit customer information to the States into which they ship the cigarettes.” Id.
The City of New York brought a RICO claim against one such vendor, alleging the
vendor’s failure to file the required report “constitute[d] . . . fraud, which caused
[the City] to lose tens of millions of dollars in unrecovered cigarette taxes.” See id.
62. See id. at 11 (discussing causation). The Supreme Court noted “the disconnect between the asserted injury and the alleged fraud in this case [was] even
sharper than in Anza” because there were multiple steps between the alleged fraud
(failure to file the required report) and the alleged injury (lost tax revenue). See
id. Specifically, the Court explained, “the defendant’s fraud on [a] third party
(the State) [ ] made it easier for a fourth party (the taxpayer) to cause harm to the
plaintiff (the City).” Id.
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Just as in Anza and Hemi Group, the plaintiffs in Bridge v. Phoenix Bond
& Indemnity Co.63 alleged harm that resulted from fraud on a third party,
but in Bridge, the Court found the plaintiffs had sufficiently pled proximate cause.64 The Bridge plaintiffs alleged that, by defrauding the county,
the defendants secured “a disproportionate share of [property] liens,”
thereby causing the plaintiffs to “[lose] valuable liens they otherwise
would have been awarded.”65 Finding it irrelevant that the plaintiffs had
not relied on the defendants’ misrepresentations, the Court explained
that proximate cause was satisfied because the “alleged injury—the loss of
valuable liens—[was] the direct result” of the alleged fraudulent scheme
against the county.66 The Court emphasized that, “unlike in Holmes and
Anza,” in the present case, there were no other factors that might account
for the injury, there was “no risk of duplicative recoveries,” and no other
“victim [was] better situated to sue.”67
D.

Family Dispute: Circuits Split on Injury and Causation

Despite the Supreme Court’s extensive consideration of RICO proximate cause, lower courts continue to struggle with the concept.68 As the
Holmes Court recognized, determining RICO proximate cause requires assessing the “directness of [the] relationship” between the alleged fraudulent conduct and the asserted injury.69 Accordingly, courts address the
issues of injury and causation in tandem, and in cases like Avandia, two
63. 553 U.S. 639 (2008).
64. See supra notes 58–62 and accompanying text for a discussion of Anza and
Hemi Grp. and infra notes 65–67 and accompanying text for a discussion of Bridge.
65. See Bridge, 553 U.S. at 643–44, 649. The dispute in Bridge arose over an
annual auction in which the county “sells tax liens it has acquired on the property
of delinquent taxpayers.” See id. at 642. “[B]ids are stated as percentage penalties
the property owner must pay the winning bidder in order to clear the lien,” and
“[t]he bidder willing to accept the lowest penalty wins the auction and obtains the
right to purchase the lien in exchange for paying the outstanding taxes on the
property.” Id. Consequently, all bidders bid zero percent (0%), and the auction
always results in a tie. See id. (explaining bidding process). To address this dilemma, the county “allocate[s] parcels ‘on a rotational basis’ in order to ensure
that liens are apportioned fairly among 0% bidders.” See id. at 643. To ensure
fairness, the county “requires each ‘tax buying entity’ to submit bids in its own
name and prohibits it from using ‘apparent agents, employees, or related entities’
to submit simultaneous bids for the same parcel.” See id. The Bridge plaintiffs alleged the defendants violated this rule and sent “hundreds of mailings in furtherance of [a] scheme” to defraud the county into awarding the defendants “a
disproportionate share of liens,” thereby causing the plaintiffs to “[lose] valuable
liens they otherwise would have been awarded.” See id. at 644, 649.
66. See id. at 655–58 (noting lack of “common–law principle holding that a
fraudulent misrepresentation can cause legal injury only to those who rely on it”).
67. See id. at 658.
68. See infra notes 69–138 and accompanying text for a discussion of attempts
by circuit courts to apply the Supreme Court’s proximate cause standard.
69. See Holmes v. Sec. Inv’r Prot. Corp., 503 U.S. 258, 269 (1992) (discussing
RICO causation element).
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theories of injury have emerged: the “excess price” and the “quantity effect” theories.70
Under the excess price theory, a plaintiff alleges paying a higher price
for a good or service than it would have, absent the defendant’s misrepresentations.71 Under the quantity effect theory, a plaintiff alleges paying
for a greater quantity of a product or service than it would have, absent the
defendant’s fraud.72 Both the Second and Third Circuits have historically
rejected both theories, while the First Circuit has embraced them.73
Claims brought under the excess price or quantity effect theory tend
to fail because the plaintiff cannot show actual—as opposed to theoretical—harm.74 For example, in Maio v. Aetna, Inc.,75 decided fifteen years
before Avandia, the Third Circuit considered a class action brought by a
group of insured individuals against their insurer.76 The insureds alleged
that they had overpaid for insurance plans because their insurer fraudulently misrepresented certain qualities of the plans.77 The Third Circuit
rejected the excess price theory, reasoning that in order to show the plans
were actually less valuable than the price paid, the insureds had to prove
70. See infra notes 71–72 and accompanying text for a description of the excess price and quantity effect theories of injury.
71. See, e.g., UFCW Local 1776 v. Eli Lilly & Co., 620 F.3d 121, 129 (2d Cir.
2010) (explaining excess price injury as “the monetary difference between what
the plaintiff class was allegedly led to believe [a drug] was worth and the actual
economic value of [the drug], taking into account the lesser efficacy and greater
harmful side effects allegedly hidden or misrepresented by [the manufacturer]”).
72. See, e.g., id. (explaining quantity effect injury allegedly incurred “by paying
for [a drug] that would not have been prescribed but for” manufacturer’s
misrepresentations).
73. See infra notes 75–99 and accompanying text for a discussion of excess
price and quantity effect theories of damages in civil RICO claims.
74. See infra notes 75–92 and accompanying text for a discussion of cases
where the excess price and/or quantity effect theories failed.
75. 221 F.3d 472 (3d Cir. 2000).
76. See id. at 474 (explaining plaintiffs brought class action against insurer
Aetna for alleged RICO violations).
77. See id. at 474–75, 484 (describing plaintiffs’ claims). The insureds alleged
that Aetna violated RICO through a “massive nationwide fraudulent advertising
campaign designed to induce” them to enroll in Aetna’s health management organization (HMO) plan. See id. at 474. The insureds claimed they paid the HMO’s
premium in reliance on Aetna’s false representation that the plan had certain
qualities such as financial incentives for physicians to provide high quality care. See
id. at 474–75 (“[The insureds] also assert that Aetna represented that HMO members would receive high quality health care . . . .”). In reality, the insureds alleged,
the plan lacked many of the valuable qualities and benefits promised and was,
therefore, less valuable than the price paid. See id. (describing allegations by insureds that “in reality Aetna’s internal policies restrict[ed] the physicians’ ability to
provide the high quality health care that [the insureds] [had] been promised”).
The court explained the insureds’ theory of damages as follows: “[A]ppellants’
argument with respect to the damage element of their RICO claims is that they
have standing under RICO because they paid too much in their premium dollars
for the health insurance they received from Aetna.” Id. at 484.
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“each appellant suffered negative medical consequences.”78 Without
proving “diminished benefits or care,” the insureds “simply [could not]
establish . . . that they received anything less than what they bargained
for.”79
The Third Circuit expressed total confidence in its holding.80 Specifically, the court emphasized it had no doubt about its resolution regarding
the “damages theory.”81 Moreover, the court stressed that allowing the
plaintiffs’ excess price claims to proceed would mean “expanding the concept of RICO injury beyond the boundaries of reason.”82
More than a decade later, the Third Circuit reaffirmed its utmost confidence in Maio when it decided In re Schering Plough Corp. Intron/Temodar
Consumer Class Action.83 In Schering, a class of TPPs brought a RICO claim
against a drug manufacturer, alleging injury because the drug company
fraudulently induced physicians to prescribe certain medications for offlabel uses.84 The court dismissed the claims on other grounds but noted,
in dictum, that “the TPP Complaint did not allege a concrete injury” because there was no evidence that “the drugs . . . were actually ineffective or
otherwise worth less than what they paid for them.”85
Presented with nearly identical facts in UFCW Local 1776 v. Eli Lilly &
Co.86 and Sergeants Benevolent Ass’n Health & Welfare Fund v. Sanofi-Aventis
78. See id. at 474, 487–88 (explaining Court’s reasoning). The court affirmed
the complaint’s dismissal because “appellants [had] not alleged an injury to business or property cognizable under RICO.” See id. at 474. The Court explained,
“that unless appellants claim[ed] that Aetna failed to provide sufficient health insurance coverage to the members of their HMO plan in the sense that such individuals were denied medically necessary benefits, received inadequate, inferior or
delayed medical treatment, or even worse, suffered personal injuries,” then there
was no “factual basis for appellants’ conclusory allegation that they have been injured in their ‘property’ because the health insurance they actually received was
inferior and therefore ‘worth less’ than what they paid for it.” Id. at 488.
79. See id. at 494.
80. See id. at 496 (noting there was not “any doubt concerning the result”).
81. See id. (asserting no “doubt concerning the result . . . with respect to the
message underlying appellants’ damages theory”).
82. See id. at 495–96 (emphasis added).
83. 678 F.3d 235 (3d Cir. 2012).
84. See id. at 241–42 (describing plaintiffs’ claims). The plaintiffs claimed
“that Schering’s unlawful marketing practices caused physicians to prescribe the
Subject Drugs for off–label uses instead of equally effective alternative treatments
that were approved for the prescribed uses.” Id. at 242. The plaintiffs “assert[ed]
that these marketing techniques led to a significant increase in prescriptions of the
Subject Drugs for off–label uses, and contend[ed] that this caused the Plaintiffs
‘ascertainable loss’ because they paid ‘hundreds of millions, if not billions, of dollars for the Subject Drugs that they otherwise would not have paid.’ ” Id. An
“off–label” use of a prescription medication occurs when a physician prescribes the
drug for a use other than an FDA–approved use. See UFCW Local 1776 v. Eli Lilly
& Co., 620 F.3d 121, 127 (2d Cir. 2010) (explaining off–label use). Although
“off–label prescriptions are permitted within a physician’s discretion, drug manufacturers are prohibited from promoting off–label uses.” Id.
85. See Schering, 678 F.3d at 246 (emphasis added).
86. 620 F.3d 121 (2d Cir. 2010).
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U.S. LLP,87 the Second Circuit also rejected both an excess price and a
quantity effect theory of damages.88 In both cases, a class of TPPs alleged
injury due to a manufacturer’s misrepresentations about the safety of a
particular drug.89 In considering the excess price theory, the court described the long causal chain as follows: (1) the manufacturer allegedly
distributed misinformation; (2) in reliance on this misinformation, the
Pharmacy Benefit Managers (PBMs) recommended the TPPs place the
drug on their formularies; (3) the TPPs placed the drug on their formularies in reliance on the PBMs’ advice; (4) physicians prescribed the drug in
reliance on the manufacturer’s misrepresentations; and (5) the TPPs consequently overpaid.90 The court concluded proximate cause was lacking
under Hemi Group, noting the TPPs’ “theory of liability rest[ed] on the
independent actions of third and even fourth parties” and was thus too
attenuated.91 Likewise, under the quantity effect theory, the court held
“the independent actions of prescribing physicians” interrupted the causal
chain and “thwart[ed] any attempt to show proximate cause.”92
87. 806 F.3d 71 (2d Cir. 2015).
88. See infra notes 89–92 and accompanying text for a discussion of Sergeants
and UFCW.
89. See Sergeants, 806 F.3d at 74 (“Plaintiffs–Appellants are three
health–benefit plans [ ] that brought suit under [RICO] . . . claiming that Defendants–Appellees . . . engaged in a pattern of mail fraud by failing to disclose the true
risks of the antibiotic drug telithromycin, marketed as ‘Ketek.’ ”); UFCW, 620 F.3d
at 123 (“Plaintiffs–appellees . . . (‘TPPs’) who underwrite the purchase of prescription drugs by their members or insureds, brought this putative class action against
Eli Lilly and Company (‘Lilly’), manufacturer of the drug Zyprexa, alleging that
Lilly had misrepresented Zyprexa’s efficacy and side effects to physicians.”).
90. UFCW, 620 F.3d at 134 (describing “attenuated link between the alleged
misrepresentations made to doctors and the ultimate injury to the TPPs”). The
court noted that the drug manufacturer, physicians, TPPs, PBMs, and PBM Pharmacy and Therapeutics Committees all had a role in the chain of causation. See id.
(describing chain of causation). The court explained, “TPPs typically pay for a
prescribed medication only if the drug is authorized under their formulary, a list
of medications approved for payment.” Id. “The formulary is usually managed by
a Pharmacy Benefit Manager (“PBM”).” Id. “Drugs placed on a formulary are approved by the PBM’s Pharmacy and Therapeutics Committee, made up of physicians and clinical pharmacists.” Id. “PBMs maintain their formulary based upon
publicly available clinical information, which is . . . produced and disseminated by
the drug manufacturers themselves.” Id.
91. See id. (quoting Hemi Grp., LLC v. City of New York, 559 U.S. 1, 14
(2010)) (internal quotation marks omitted).
92. See id. at 135 (discussing causation). In rejecting the quantity effect theory in Sergeants, the court reasoned the alleged injury required proof that doctors
prescribed the drug in reliance on the manufacturer’s non–disclosure of the
drug’s true risks. See Sergeants, 806 F.3d at 91 (discussing required showing under
quantity effect theory). The Second Circuit applied its UFCW precedent, explaining that, in UFCW, the court “held that this generalized proof—which showed a
simple correlation between the safety disclosure and the decline in prescriptions—
was not enough for the plaintiffs to prove that each class member was injured by
[the] alleged misrepresentations, in light of the multifaceted and individualized
nature of physicians’ prescribing decisions.” See id. at 92. The court determined
the same logic applied in Sergeants, noting “Ketek’s declining sales may have been
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While the Second and Third Circuits have approached injury and
causation conservatively, the First Circuit has embraced a more expansive
view.93 Under facts similar to those of Maio, Schering, UFCW, and Sergeants,
the First Circuit readily accepted the quantity effect theory.94 In In re
Neurontin Marketing & Sales Practices Litigation,95 a TPP alleged a drug company’s fraud caused more prescriptions to be written—and paid for by the
TPP—than would have been, absent the fraud.96 The drug manufacturer
argued that, as a matter of law, the TPP failed to meet the Holmes “proximate cause ‘direct relation’ requirement” because “the causal relationship
[involved] at least four steps.”97 The court rejected this attenuated chain
argument, finding proximate cause was met under Bridge.98 The court
reasoned that, like the competing bidders in Bridge, here, the TPP was the
“primary and intended victim [ ] of [the manufacturer’s] scheme to decorrelated with the issuance of the FDA’s public health advisory and with Ketek’s
label revisions, but mere correlation does not demonstrate causation.” See id.
93. See supra notes 75–92 and accompanying text for a discussion of Second
and Third Circuit precedent. For a discussion of First Circuit precedent, see infra
notes 94–99 and accompanying text.
94. See infra notes 95–99 and accompanying text for a discussion of the First
Circuit’s acceptance of the quantity effect theory of injury in a civil RICO case.
Note that the relevant First Circuit case, In re Neurontin Marketing & Sales Practices
Litigation, was decided prior to Sergeants. Compare Sergeants, 806 F.3d 71 (rendering
holding in 2015), with In re Neurontin Mktg. & Sales Practices Litig., 712 F.3d 21
(1st Cir. 2013) (rendering holding two years prior to Sergeants). The Second Circuit distinguished Sergeants from Neurontin, noting that Neurontin did not involve
class certification and the Neurontin plaintiffs presented expert testimony of sophisticated regression analysis that supported a reasonable finding of “a causal effect”
between the drug company’s off–label promotional activities and “prescribing behaviors” of individual physicians. See Sergeants, 806 F.3d at 96 (quoting Neurontin,
712 F.3d at 45). The Second Circuit expressly reserved ruling on whether aggregated regression analysis would ever be sufficient to prove proximate cause in a
RICO claim involving a class of plaintiffs, but found the proffered causation evidence in Sergeants “akin to the simplistic proof introduced by the [UFCW] plaintiffs” and insufficient for proximate cause. See id. at 97 (finding “RICO causation”
lacking).
95. 712 F.3d 21 (1st Cir. 2013).
96. See id. at 25 (“This is an appeal from verdicts of over $140 million, reached
by both a jury and a court, compensating Kaiser . . . for the injury Kaiser suffered
by its payment for four categories of off–label Neurontin prescriptions . . . induced
by a fraudulent scheme by Pfizer, the manufacturer of Neurontin.”).
97. See id. at 38. The court explained Pfizer’s characterization of the causal
chain as follows: “Pfizer communicating tainted information about Neurontin to
Kaiser’s DIS; the DIS producing monographs that rely on the misrepresentations;
those monographs influencing the PMGs in their formulary decisions; and the prescribing physicians (who exercise independent medical judgment) acting within
the formulary to issue the prescriptions.” See id. DIS stands for Drug Information
Service, and PMG stands for Permanente Medical Groups (regional physician
groups that “have exclusive contractual relationships with Kaiser”). See id. at
28–29.
98. See id. at 38–39 (“[T]he causal chain in this case is anything but
attenuated.”).
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fraud” and “there [was] no risk of multiple recoveries due to a suit by
another [party].”99
III. THE THIRD CIRCUIT FLIPS: AVANDIA OVERVIEW & ANALYSIS
Presented with facts much like those in Maio, Schering, UFCW, Sergeants, and Neurontin, the Third Circuit changed course in Avandia and
abandoned its conservative civil RICO precedent.100 As in Maio and Schering, the court focused its analysis on injury and proximate cause.101 Despite the highly similar facts and damages, however, the Avandia court was
not concerned about “expanding the concept of RICO injury beyond the
boundaries of reason.”102 Rather, the court relied on general language from
a prior antitrust decision to conclude the plaintiffs had alleged a concrete
injury.103 Furthermore, like the First Circuit in Neurontin, the Third Circuit relied on Bridge to find proximate cause in Avandia.104
99. See id. at 37 (footnote omitted).
100. See supra notes 75–99 and accompanying text for a discussion of Maio,
Schering, UFCW, Sergeants, and Neurontin. For a discussion and critical analysis of
Avandia, see infra notes 101–38 and accompanying text. See also James M. Beck,
“Destroying Things Is Much Easier Than Making Them”—The Worst Prescription Drug/
Medical Device Decisions of 2015, LEXOLOGY (Dec. 24, 2015), http://www.lexology.
com/library/detail.aspx?g=96e8999a-2586-4dd4-ba69-7e81691f61b5 [https://per
ma.cc/X5ZQ-G3HD] (criticizing Third Circuit’s Avandia decision). Mr. Beck,
Counsel Resident at Reed Smith in Philadelphia, lamented that “[u]ntil [the
Avandia] decision, we thought the Third Circuit was one of the better places to
litigate third–party payer economic loss cases.” See id. He went on to explain that
“[i]n all prior Third Circuit decisions of this type, the patient–specific decisions of
independent professional physicians had precluded resort to aggregated statistical
proof of injury and causation,” but “[n]ot this time.” Id. In a related blog, John J.
Sullivan, a commercial litigator at Cozen O’Connor in Philadelphia, elaborated on
the matter, explaining that the Third Circuit had previously “resisted [the] trend”
of “awkwardly extending [RICO’s] civil reach into areas and transactions for which
RICO was seemingly never intended.” See John J. Sullivan, The Third Circuit Does an
About–Face on RICO Claims, DRUG AND DEVICE LAW (Dec. 7, 2015), https://www.
druganddevicelawblog.com/2015/12/the-third-circuit-does-about-face-on.html [ht
tps://perma.cc/68EF-X3AN]. According to Mr. Sullivan, with its Avandia decision, “the Third Circuit scuttled its previous good work and stretched RICO’s arms
all the way out to reach consumer disputes with pharmaceutical manufacturers.”
See id.
101. See In re Avandia Mktg., Sales Practices & Prod. Liab. Litig., 804 F.3d 633,
638–46 (3d Cir. 2015) (“In addition to cognizable injury, a RICO plaintiff must
satisfy RICO’s proximate causation requirements.”), cert. denied sub nom. GlaxoSmithKline LLC v. Allied Servs. Div. Welfare Fund, 136 S. Ct. 2409 (2016).
102. See Maio v. Aetna, Inc., 221 F.3d 472, 495–96 (3d Cir. 2000) (emphasis
added); Avandia, 804 F.3d at 640 (“[U]nlike the injury suffered by plaintiffs in
Maio, the injury suffered by the TPPs here is not contingent on future events.”).
103. See Avandia, 804 F.3d at 640–41 (finding concrete injury in reliance on In
re Warfarin Sodium Antitrust Litig., 391 F.3d 516, 531 (3d Cir. 2004)).
104. See id. at 644 (“[W]e view the case before us as more akin to Bridge than
to Holmes, Anza, or Hemi.”). For a discussion of the First Circuit’s Neurontin decision, see supra notes 94–99 and accompanying text.
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Let’s Take a Walk: Facts and Procedural History

In Avandia, a class of TPPs brought civil RICO claims against pharmaceutical behemoth GlaxoSmithKline (GSK), alleging GSK fraudulently
misrepresented the safety of its drug Avandia.105 The TPPs asserted both
excess price and quantity effect theories.106 GSK filed a motion to dismiss,
claiming the TPPs lacked standing because they had not sufficiently pled
either (1) an injury to business or property or (2) proximate cause.107
The district court rejected both arguments, finding the TPPs “plausibly alleged . . . a concrete economic injury based on the substantial savings
they would have experienced had they covered cheaper alternatives to
Avandia.”108 The lower court also concluded the TPPs’ economic injury
existed “regardless of whether any beneficiary who had ingested Avandia
became ill.”109 Additionally, the district court found the TPPs had adequately pled proximate cause, but noted causation may be difficult to
prove “at the next litigation stage.”110
The Third Circuit entertained review on interlocutory appeal, addressing three questions: (1) whether the district court erred in applying
Maio; (2) whether the TPPs sufficiently pled a concrete injury; and
(3) whether “the independent judgment of doctors . . . who wrote the
prescriptions for Avandia render[ed] the causal chain too attenuated to
state a claim.”111
B.

GSK Gets Pinched: A Narrative Analysis

The court rejected GSK’s argument that, under Maio, the TPPs failed
to allege a concrete “injury to business or property.”112 According to the
court, Maio was easily distinguishable.113 In Maio, the court explained, the
insureds could not prove overpayment for their insurance plans without
105. See Avandia, 804 F.3d at 634 (“This interlocutory appeal involves claims
brought against GlaxoSmithKline LLC (GSK) by third–party payors (TPPs), based
on GSK’s alleged misrepresentation and concealment of the significant safety risks
associated with use of Avandia.”).
106. See id. at 636 (describing plaintiffs’ claim “that Avandia was worth less
than the favorable rates at which they covered it (their ‘excess price’ theory)” and
“that physicians relied on GSK’s misrepresentations in deciding to prescribe
Avandia and would have prescribed Avandia to fewer patients had GSK not concealed Avandia’s risks (their ‘quantity effect’ theory)”).
107. See id. at 637 (describing procedural history).
108. See id. (discussing district court’s holding).
109. See id. (discussing district court’s finding of plausible allegation of concrete economic injury).
110. See id. (“The District Court noted, however, that plaintiffs may have difficulty in proving causation at the next litigation stage . . . .”).
111. See id. (listing questions certified for review).
112. See id. at 638–41 (rejecting defendant’s claim that plaintiff failed to plead
concrete injury).
113. See id. at 640 (“Maio is distinguishable in one crucial respect: unlike the
injury suffered by plaintiffs in Maio, the injury suffered by the TPPs here is not
contingent on future events.”).
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showing they actually received subpar medical care.114 By contrast, the
Avandia court concluded that the TPPs in this case did not need to show
the drug was actually ineffective or less safe in order to prove
overpayment.115
In reaching this conclusion, the court disregarded Maio and relied
instead on general language from an antitrust case, In re Warfarin Sodium
Antitrust Litigation.116 In Warfarin, the Third Circuit concluded that TPPs
suffer “direct economic harm” when anticompetitive behavior induces
them to buy more expensive brand name drugs instead of lower-priced
generics.117 Thus, the Avandia court concluded, “if allegedly anticompetitive behavior that leads to overpayment establishes a concrete injury, then
so should allegedly fraudulent behavior that leads to overpayment.”118
The court then summarily dismissed Schering, merely noting the relevant findings in that case were dicta.119 Notably, the Schering court determined “the plaintiffs lacked standing to assert . . . injury because they failed to
allege that any consumers or beneficiaries received inadequate drugs.”120 Because
this conclusion was in dictum, the Avandia court determined any reliance
on it would be “misplaced.”121
The court next turned to the issue of causation and concluded that,
unlike Holmes, Anza, and Hemi Group—cases in which proximate cause was
114. See id. at 639–40 (explaining Maio holding). The court explained that in
Maio, it “found that the insured parties had suffered no injury absent allegations
that they had received ‘inadequate, inferior delayed care, personal injuries resulting therefrom, or [the] denial of benefits due under the insurance arrangement.’ ”
Id. at 639.
115. See id. at 640 (“The TPPs’ damages do not depend on the effectiveness of
the Avandia that they purchased, but rather on the inflationary effect that GSK’s
allegedly fraudulent behavior had on the price of Avandia.”).
116. See id. at 639–40 (“We agree with the TPPs that Warfarin [an antitrust
case] offers the closest analogy to the facts of this case and that GSK’s reliance on
Maio is distinguishable . . . .” (relying on In re Warfarin Sodium Antitrust Litig., 391
F.3d 516 (3d Cir. 2004))).
117. See id. (applying Warfarin, 391 F.3d at 531). Warfarin involved antitrust
claims against DuPont, the maker of Coumadin (the brand name version of warfarin). See Warfarin, 391 F.3d at 521 (discussing plaintiffs’ claims). The plaintiffs
“allege[d] that DuPont’s anticompetitive behavior . . . caused them to purchase
the higher–priced Coumadin instead of the generic product.” Id. The case consolidated a class of consumers and a class of TPPs. See id. at 523 (describing procedural history of case). In considering an objection to the inclusion of the TPPs in
the class, the court explained that “TPPs, like individual consumers, suffered direct
economic harm when, as a result of DuPont’s alleged misrepresentations, they
paid supracompetitive prices for Coumadin instead of purchasing lower-priced generic warfarin sodium.” See id. at 531.
118. See Avandia, 804 F.3d at 640.
119. See id. (citing In re Schering Plough Corp. Intron/Temodar Consumer
Class Action, 678 F.3d 235, 246 (3d Cir. 2012)) (“To the extent we agreed with the
District Court’s injury analysis in [Schering], we did so in dictum, not in binding
precedent.”).
120. See id. (emphasis added) (describing reasoning in Schering).
121. See id. (rejecting reliance on Schering).
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lacking because the alleged harm was too attenuated—the TPPs in this
case had alleged a direct injury analogous to that alleged in Bridge.122 The
court dismissed the argument that the causal chain was broken by the decisions of prescribing physicians.123 Rather, the court reasoned, “Bridge
preclude[d] that argument” because, just as in Bridge, the plaintiffs here
“were the ‘primary and intended victims of the scheme to defraud.’”124
The court held that because the success of the fraudulent scheme depended on the TPPs’ paying for Avandia, the alleged injury was “sufficiently direct to satisfy the RICO proximate cause requirement.”125
Having concluded the plaintiffs adequately pled injury and proximate
cause, the Third Circuit rejected GSK’s motion to dismiss.126 Interestingly, the court reserved “opin[ing] on the likelihood of plaintiffs’ [future] success,” noting “these issues [would] resurface” at later stages of
litigation.127
IV. MUCKED UP HIT? ANALYSIS

OF THE

COURT’S REASONING

The Avandia court made several missteps in what one group of litigators deemed the third worst legal decision of 2015.128 First, the court
provided a lengthy attempt to distinguish Avandia from Maio.129 After
describing two identical fact patterns, however, the court somehow con122. See id. at 643–44 (“The conduct that allegedly caused plaintiffs’ injuries is
the same conduct forming the basis of the RICO scheme alleged in the complaint—the misrepresentation of the heart–related risks of taking Avandia that
caused TPPs and PBMs to place Avandia in the formulary.”).
123. See id. at 644 (rejecting argument that “the presence of intermediaries—
physicians and patients” broke causal chain).
124. See id. at 645 (quoting Bridge v. Phoenix Bond & Indem. Co., 553 U.S.
639, 650 (2008)).
125. See id. (citing In re Neurontin Mktg. & Sales Practices Litig., 712 F.3d 21,
37–38 (1st Cir. 2013)) (finding proximate cause requirement satisfied due to “sufficiently direct” relationship).
126. See id. at 646 (“Plaintiffs have plausibly alleged the elements of RICO
standing, and GSK has not offered a valid justification for limiting the claims at this
stage of the litigation. . . . We simply hold that it would be premature to dismiss
plaintiffs’ well–pled RICO allegations at this juncture.”).
127. See id. The court’s apparent reservations about the plaintiffs’ future ability to prove injury and proximate cause stand in stark contrast to the utmost certainty the court expressed in its Maio holding. For a discussion of the court’s
opinion in Maio, see supra notes 80–82 and accompanying text.
128. See Beck, supra note 100 (“For taking safety, effectiveness, and concrete
injury out of the RICO equation, after years of getting this right, the Third Circuit’s Avandia decision nails down the #3 spot on our bottom ten.”).
129. See In re Avandia Mktg., Sales Practices & Prod. Liab. Litig., 804 F.3d 633,
639–40 (3d Cir. 2015) (distinguishing Maio), cert. denied sub nom. GlaxoSmithKline
LLC v. Allied Servs. Div. Welfare Fund, 136 S. Ct. 2409 (2016). According to the
court, “[t]he TPPs’ damages do not depend on the effectiveness of the Avandia
that they purchased, but rather on the inflationary effect that GSK’s allegedly
fraudulent behavior had on the price of Avandia.” Id. at 640. “By contrast,” the
court explained, “the damages suffered by the plaintiffs in Maio were entirely dependent on the quality of the health care they received.” Id.
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cluded the plaintiffs in Maio could have shown injury only by proving they
received less than they bargained for, while no similar showing was required in Avandia.130 Perhaps finding this manufactured distinction insufficient, the court then shirked its own civil RICO precedent and relied
instead on general language from antitrust litigation to arrive at its cursory
conclusion that concrete injury had been alleged.131
Turning to proximate cause, the court determined Bridge was controlling, readily dismissing Holmes, Anza, and Hemi Group.132 The court’s reliance on Bridge, however, belies two key distinctions.133 The court
erroneously concluded that, like the Bridge plaintiffs, the Avandia plaintiffs
were the primary intended victims of the fraudulent scheme and the only
group harmed and positioned to sue.134 In fact, several additional victims
are readily-identifiable.135 For example, patients who took Avandia undoubtedly paid a higher co-pay than they would have, absent the fraud.136
Additionally, the manufacturers of competing drugs were harmed when
physicians prescribed Avandia over their own drugs.137 In short, the al130. See id. (distinguishing Avandia from Maio despite similar facts and concluding that “Warfarin offers the closest analogy to the facts of this case”). One
group of legal scholars explained the insufficiency of the Third Circuit’s attempt
to distinguish Avandia from Maio, noting they “[understood] the words that the
court wrote” but simply did not “get the distinction.” See Sullivan, supra note 100
(criticizing reasoning in Avandia decision). According to Mr. Sullivan and his colleagues, in the same way “the Maio plaintiffs’ RICO damages depended entirely on
the quality of the healthcare that they [ultimately] received,” the “Avandia plaintiffs’ RICO damages also depended entirely on the quality—effectiveness and
safety—of the Avandia that they received.” See id. “In each case, the plaintiffs
claimed that the alleged misrepresentations inflated the price of the product or
service that they received.” Id. Under the Maio reasoning then, “in each case, if
they received what was represented to them, they were not damaged.” See id.
Thus, “just as the Maio plaintiffs had to show that they got lesser care than promised to show a concrete injury, the Avandia plaintiffs should have been required to
show that the Avandia they received performed less safely and effectively than
promised.” Id.
131. See Avandia, 804 F.3d at 638–41 (relying on general language from antitrust litigation rather than civil RICO precedent).
132. See supra notes 122–25 and accompanying text for a discussion of the
Avandia court’s proximate cause analysis.
133. See infra notes 134–37 and accompanying text for a discussion of key
distinctions between Bridge and Avandia not addressed by the court.
134. See infra notes 136–37 and accompanying text for examples of other
victims who could potentially sue.
135. See infra notes 136–37 and accompanying text for a discussion of readily–identifiable victims.
136. See Avandia, 804 F.3d at 636 (“A one–month supply of Avandia has sold
for $90 to $220, with the TPP covering between $135 and $140 per prescription
and the patient paying the balance.” (emphasis added)).
137. See, e.g., Bridge v. Phoenix Bond & Indem. Co., 553 U.S. 639, 649–50
(2008) (describing injury to competitor by fraud on third–party). In Bridge, the
Court held that a plaintiff need not show reliance on the defendant’s misrepresentations in order to recover. See id. at 648 (accepting third–party reliance). The
Court provided an example to explain its reasoning, suggesting that a business,
“want[ing] to get rid of rival businesses” might “mail[ ] misrepresentations about
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leged scheme had many identifiable victims, and the risk of duplicative
recoveries was high—two key factors absent in Bridge and critical reasons
proximate cause was found lacking in Holmes, Anza, and Hemi Group.138
V.

A CONSIGLIERE’S PRACTICAL GUIDANCE

FOR

ATTORNEYS

At first glance, the Avandia decision reads like an absolute win for
plaintiffs and an utter defeat for defendants.139 However, a closer examination suggests plaintiffs should proceed cautiously with Avandia-type
RICO claims, while defendants should not give up the fight.140 Avandia
raises unique considerations for plaintiffs and defendants, but all litigators
should be mindful of Rule 11 and proximate cause as two weapons at the
forefront of this ongoing battle.141
A.

Don’t Eat Alone: Guidance for Plaintiffs’ Counsel

For plaintiffs’ attorneys, the Avandia decision provides strong precedent for expansive use of civil RICO, but responsible attorneys should be
mindful of (1) the ethical implications of pushing civil RICO too far beyond its intended bounds; (2) the possibility of Rule 11 sanctions; and
(3) strong injury and causation arguments that opposing counsel may still
advance.142
Although Avandia opens the door to plaintiffs asserting all manner of
“novel and creative” claims, plaintiffs’ attorneys should—in the words of
the Eleventh Circuit—“stop and think before filing them.”143 In Maio, the
Third Circuit rejected the plaintiffs’ theory of injury as “expanding the
them to their customers and suppliers, but not to the rivals themselves.” See id. at
648–50. According to the Court, “[i]f the rival businesses lose money as a result of
the misrepresentations, it would certainly seem that they were injured in their business ‘by reason of’ a pattern of mail fraud, even though they never received, and
therefore never relied on, the fraudulent mailings.” Id. at 649–50.
138. See supra notes 48–67 and accompanying text for a discussion of the
Court’s handling of proximate cause in Holmes, Anza, Hemi Group, and Bridge.
139. See supra notes 112–38 and accompanying text for an analysis of the
Avandia decision.
140. See infra notes 142–78 and accompanying text for a discussion of practical considerations for litigators in light of the Avandia decision.
141. See infra notes 142–78 and accompanying text for a discussion of the
practical implications of the Avandia decision for both plaintiffs’ and defense
attorneys.
142. See infra notes 143–58 and accompanying text for a discussion of practical implications of Avandia for plaintiffs’ attorneys.
143. See Pelletier v. Zweifel, 921 F.2d 1465, 1522 (11th Cir. 1991) (imposing
Rule 11 sanctions for “baseless” civil RICO claim); see also MODEL RULES OF PROF’L
CONDUCT r. 3.1 (2013) (prohibiting frivolous claims). In relevant part, Model Rule
3.1 provides, “[a] lawyer shall not bring or defend a proceeding, or assert or controvert an issue therein, unless there is a basis in law and fact for doing so that is
not frivolous, which includes a good faith argument for an extension, modification or reversal of existing law.” Id. (emphasis added).
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concept of RICO injury beyond the boundaries of reason.”144 Although the
court accepted a nearly-identical theory in Avandia, this issue should give
ethically-minded attorneys reason to pause.145 With its promise of treble
damages, attorney’s fees, and access to federal court, civil RICO presents a
“powerful incentive . . . to bring facts traditionally thought to establish
other causes of action within the ambit of the statute.”146 Many courts
have cautioned attorneys to beware of the “powerful, if not [irresistible],
temptation to bring civil suits under RICO.”147 Litigators should heed this
advice and consider their ethical obligations before advancing creative
and expansive RICO claims.148
Of course, ethics tend to be personal and subject to fluid interpretation, so plaintiffs’ counsel should also beware of Rule 11 sanctions lurking
in the background.149 Many civil RICO critics have advocated increased
use of Rule 11 to deter civil RICO abuse, and a number of courts have
answered this call.150 For example, the Eleventh Circuit upheld Rule 11
sanctions against attorneys representing journalists who were injured
when a press meeting was bombed, allegedly due to the racketeering activity of the Central Intelligence Agency.151 Less dramatic examples include
sanctions against attorneys for customers unhappy with Victoria’s Secret’s
pricing structure, employees distraught with former employers, and a
board member estranged from a non-profit group.152 If the number of
144. See Maio v. Aetna, Inc., 221 F.3d 472, 495–96 (3d Cir. 2000) (emphasis
added).
145. See supra notes 129–30 and accompanying text for a critique of the
court’s attempt to distinguish Avandia from Maio despite nearly identical theories
of injury.
146. See Rehnquist, supra note 3; see also Pelletier, 921 F.2d at 1522 (“[W]ith
regard to civil RICO claims, plaintiffs must stop and think before filing
them. . . . When used improperly . . . [civil RICO] provisions allow a complainant
to shake down his opponent and . . . extort a settlement.”).
147. See, e.g., Gramercy 222 Residents Corp. v. Gramercy Realty Assocs., 591 F.
Supp. 1408, 1413 (S.D.N.Y. 1984) (“Obviously, the potential for treble damages
and attorneys’ fees is a powerful, if not [irresistible], temptation to bring civil suits
under RICO.”); see also Chapman & Cole v. Itel Container Int’l B.V., 865 F.2d 676,
685 (5th Cir. 1989) (“Given the resulting proliferation of civil RICO claims and the
potential for frivolous suits in search of treble damages, greater responsibility will
be placed on the bar to inquire into the factual and legal bases of potential claims
or defenses . . . or risk sanctions for failing to do so.” (quoting Black &
Magenheim, Using the RICO Act in Civil Cases, 22 HOUS. LAW. 20, 24–25 (1984)
(internal quotation marks omitted))).
148. See supra notes 143–47 and accompanying text for a discussion of ethical
reasons to proceed cautiously with novel or creative civil RICO claims.
149. See FED. R. CIV. P. 11 (granting courts broad discretion to impose sanctions for frivolous claims).
150. For a discussion of critics calling for increased use of Rule 11 sanctions
to deter civil RICO abuse, see supra note 40 and accompanying text.
151. See Avirgan v. Hull, 932 F.2d 1572 (11th Cir. 1991) (“On this record, we
have no difficulty in finding that these appellants unreasonably and vexatiously
multiplied these proceedings.”).
152. See, e.g., O’Malley v. N.Y.C. Transit Auth., 896 F.2d 704 (2d Cir. 1990)
(imposing sanctions in frivolous civil RICO claim by former employee against for-
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civil RICO cases continues to climb, more judges—many of whom detest
civil RICO—will likely follow suit in granting sanctions.153
Finally, plaintiffs’ attorneys should not rest on their laurels given that
Avandia failed to foreclose the lack-of-proximate-cause argument entirely,
and the Supreme Court has yet to address the circuit split on this issue.154
In fact, the district court in the Avandia case expressly stated that the TPPs
may have difficulty proving proximate cause at trial.155 More importantly,
however, the Supreme Court granted certiorari three times in five years,
most recently in 2010, to address civil RICO issues relating to proximate
cause.156 In total, the High Court has addressed civil RICO proximate
cause on four occasions, and only once has it found proximate cause sufficiently established.157 If the Court again entertains the proximate cause
issue, and the Court’s prior trend continues, Avandia- and Neurontin-type
RICO claims will be quashed.158
B.

Go to the Mattresses: Guidance for Defense Counsel

Although Avandia should rightfully give defense attorneys nightmares, all hope is not lost.159 Third Circuit defense counselors—particularly those who represent big pharmaceutical companies—should take
several actions in response to this case: (1) counsel clients on the implications of Avandia and urge them to advocate for legislative reform; (2) if
faced with similar litigation, focus on lack of proximate cause and be premer employer); Katzman v. Victoria’s Secret Catalogue, 167 F.R.D. 649 (S.D.N.Y.
1996) (imposing sanctions against plaintiffs alleging Victoria’s Secret’s “pricing
structures with respect to catalogues mailed to different recipients constitute[d] a
[RICO] violation”); Binghamton Masonic Temple, Inc. v. Bares, 168 F.R.D. 121,
127 (N.D.N.Y. 1996) (imposing sanctions in civil RICO action brought against
non–profit by former president).
153. See ABRAMS, supra note 20, § 1.2, at 11–14 (discussing judicial hostility
towards civil RICO); BATISTA, supra note 3, § 1.02 (“[M]any federal judges have a
distaste for civil racketeering actions.”); SHELDON, supra note 4, § 7.1.5, at 139
(“Many federal courts initially reacted with hostility to civil RICO.”).
154. See supra notes 100–38 and accompanying text for a discussion of the
Third Circuit’s Avandia decision. For a discussion of the circuit split on the issues
of injury and proximate cause, see supra notes 68–99 and accompanying text.
155. See supra note 110 and accompanying text for a discussion of the district
court’s assertion that proximate cause may be difficult to prove in later litigation
stages.
156. See supra notes 48–67 and accompanying text for a discussion of the
Supreme Court’s consideration of RICO proximate cause.
157. See supra notes 48–67 and accompanying text for a discussion of Supreme Court jurisprudence on civil RICO proximate cause.
158. See supra notes 48–67 and accompanying text for a discussion of Supreme Court jurisprudence on civil RICO proximate cause. Also, see supra notes
95–99 and accompanying text for a discussion of the Neurontin decision and supra
notes 100–38 and accompanying text for a discussion of the Avandia decision.
159. See infra notes 160–78 and accompanying text for a discussion of practical implications of the Avandia decision for defense attorneys.
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pared to seek certiorari to resolve the circuit split; and (3) call for Rule 11
sanctions.160
First and foremost, attorneys representing pharmaceutical companies
should counsel clients on the implications of Avandia and urge clients to
seek legislative reform.161 Clients should be encouraged to enact procedural safeguards to prevent the type of fraudulent activities at issue in
Avandia.162 Perhaps more importantly, attorneys should advise pharmaceutical clients to mobilize their powerful lobby to drive civil RICO reform—advocating for a return to RICO’s roots of combating organized
crime.163 To date, only the financial industry has been successful in achieving RICO reform, but like the financial lobby, Big Pharma carries weight
in Washington.164
Historically, however, Congress has resisted RICO reform for fear of
looking soft on crime.165 Given that this trend will likely continue, pharmaceutical defendants will most likely have to fight their civil RICO battles
in court.166 With its fluid and elusive definition, proximate cause should
be the defense attorney’s primary weapon in waging that war.167 Notably,
the Avandia court accepted the TPPs’ pleading of proximate cause as sufficient to survive a motion to dismiss, but acknowledged the plaintiffs may
have difficulty proving causation at trial.168
160. See infra notes 161–78 and accompanying text for a discussion of actions
defense attorneys should take in light of the Avandia decision.
161. See MODEL RULES OF PROF’L CONDUCT r. 2.1 (2013) (“In representing a
client, a lawyer shall . . . render candid advice. In rendering advice, a lawyer may
refer not only to law but to other considerations such as moral, economic, social
and political factors, that may be relevant to the client’s situation.”).
162. See id. (describing nature of advice attorneys should provide to clients).
163. See CENTER FOR RESPONSIVE POLITICS, https://www.opensecrets.org/
lobby/top.php?indexType=i [https://perma.cc/B6UK-LKDS] (last visited Feb. 3,
2016) (reporting “Pharmaceuticals/Health Products” as top lobbying industry in
Washington, DC). For a discussion of RICO’s intended use against organized
crime, see supra notes 17–22 and accompanying text.
164. See BATISTA, supra note 3, § 2.07 (“Despite decades of lobbying efforts by
business groups and others, RICO has been amended only once. Enacted over
President Clinton’s veto, the Private Securities Litigation Reform Act of 1995
(PSLRA) amended RICO to eliminate securities fraud as a predicate racketeering
offense.”); CENTER FOR RESPONSIVE POLITICS, supra note 163 (reporting
“Pharmaceuticals/Health Products” and “Securities & Investment” among top lobbying industries in Washington, DC).
165. See supra note 39 and accompanying text for a discussion of Congress’s
reluctance to amend RICO for fear of looking soft on crime.
166. See BATISTA, supra note 3, § 2.07 (noting only one substantive change to
civil RICO despite lobbying).
167. See supra notes 48–67 and accompanying text for a discussion of the
Supreme Court’s efforts to define RICO proximate cause.
168. For further discussion of the Avandia court’s reservations about the
plaintiffs’ future ability to prove causation at trial, see supra note 127 and accompanying text.
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Significantly, both the Avandia and Neurontin courts relied on Bridge
to find proximate cause in the facts before them.169 Applying Bridge, both
courts focused on the notion that the plaintiffs were the “primary and intended victims of the scheme to defraud” and that there was “no risk of
duplicative recover[y].”170 Given these same facts, however, a competent
attorney could, and should, argue that there are multiple risks for duplicative recovery.171
For example, although TPPs pay a significant percent of the cost of a
drug, insured individuals typically pay the balance and are thus directly
harmed when a pharmaceutical company engages in the type of fraudulent scheme described in Avandia and Neurontin.172 Additionally, uninsured individuals are faced with the entire cost of a fraudulentlyoverpriced medication—an issue the Neurontin court dismissed in a footnote as not presently before it.173 Finally, and perhaps most significantly,
manufacturers of competing drugs are financially harmed when a fraudulent scheme causes physicians to disproportionately prescribe a competitor’s drug over their own—a scenario precisely analogous to the
hypothetical facts described in Bridge.174 Focusing on this risk of duplicative recoveries may help to undermine application of Bridge, where the
Court specifically relied on the fact that only the plaintiffs were injured
and no others stood to recover.175
Finally, defense attorneys faced with traditional state fraud claims
cloaked in civil RICO’s clothing should call for Rule 11 sanctions.176 In
the same way an athlete asking for the foul often gets the call, defense
169. See supra notes 95–99 and accompanying text for a discussion of the
Neurontin court’s reliance on Bridge and supra notes 122–25 and accompanying text
for a discussion of the Avandia court’s similar reliance.
170. See Bridge v. Phoenix Bond & Indem. Co., 553 U.S. 639, 650, 658 (2008)
(identifying factors favorable to meeting proximate causation requirement under
civil RICO). For further discussion of the Neurontin court’s reliance on Bridge, see
supra notes 95–99 and accompanying text. For a discussion of the Avandia court’s
similar reliance on Bridge, see supra notes 122–25 and accompanying text.
171. See infra notes 172–75 and accompanying text for a discussion of the
risks of duplicative recoveries in Avandia.
172. For further discussion of the potential parties harmed by the fraudulent
schemes at issue in Neurontin and Avandia, see supra note 136 and accompanying
text.
173. See In re Neurontin Mktg. & Sales Practices Litig., 712 F.3d 21, 38 n.11
(1st Cir. 2013) (“Pfizer raised the possibility that premium payers might also sue as
victims of Pfizer’s scheme, but the question of whether any injury to such payers
was proximately caused by this scheme is not before us.”).
174. See supra note 137 and accompanying text for a discussion of the analogous case provided in Bridge, under which competing drug companies may be positioned to claim injury and sue under the facts of Avandia.
175. See supra notes 63–67 and accompanying text for a discussion of the
Court’s reasoning in Bridge.
176. See supra note 40 and accompanying text for a discussion of calls for
increased use of Rule 11 sanctions to deter civil RICO abuse.
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attorneys applying this same tactic may be pleased with the results.177
Countless legal scholars have called for use of Rule 11 sanctions to deter
civil RICO abuse, and perhaps if defense attorneys join the call to action,
increased sanctions will flow and will act as a check on civil RICO’s irresistible allure of treble damages and attorney’s fees.178
VI.

MORE HITS COMING: WHAT’S NEXT

FOR

CIVIL RICO?

Whether civil RICO cases today represent “horrible examples of overreach” is a matter of opinion, but it seems undeniably clear that this law
has evolved from specifically targeting organized crime into something
much broader.179 The Third Circuit’s Avandia decision represents yet another expansion of RICO’s scope, but the decision’s ultimate implications
remain to be seen.180 With so many Big Pharma companies concentrated
in the Third Circuit’s jurisdiction, additional Avandia-type claims will likely
follow.181 As courts continue their struggle to “decipher, administer, and
uphold” civil RICO, plaintiffs’ attorneys should exercise ethical restraint,
while defense lawyers should advocate reform aimed at putting organized
crime back in RICO’s crosshairs.182

177. See supra note 40 and accompanying text for a discussion of calls for
increased use of Rule 11 sanctions to deter civil RICO abuse.
178. For a discussion of scholars and others suggesting use of Rule 11 sanctions as a means to curb civil RICO abuse, see supra note 40 and accompanying
text.
179. See 116 CONG. REC. 35,204 (1970) (statement of Rep. Mikva)
(“[W]hatever [RICO’s] motives to begin with, we will end up with cases involving
all kinds of things not intended to be covered, and a potpourri of language by
which you can parade all kinds of horrible examples of overreach.”); see also supra
notes 1–42 and accompanying text for a discussion of RICO’s evolution from a law
aimed at the Italian–American Mafia into a statute used to bring garden variety
fraud claims against businesses.
180. See supra notes 100–38 and accompanying text for a discussion of the
Avandia case and supra notes 139–78 and accompanying text for a discussion the
case’s practical implications.
181. See, e.g., STATE OF N.J. BUS. PORTAL, http://www.nj.gov/njbusiness/indus
try/pharmaceutical [https://perma.cc/ET5E-3GMZ] (last visited Feb. 15, 2016)
(noting fourteen of twenty largest pharmaceutical companies are located in New
Jersey); see also John George, Pennsylvania Bio CEO: Shire Move a Wake–up Call,
PHILA. BUS. J. (Nov. 20, 2014, 11:30 AM), http://www.bizjournals.com/philadel
phia/blog/health-care/2014/11/pennsylvania-bio-ceo-shire-move-a-wake-up-call.
html [https://perma.cc/FV8D-VFQ2] (noting concentration of pharmaceutical
companies in Pennsylvania).
182. See supra notes 139–78 and accompanying text for a discussion of practical suggestions for litigators post–Avandia.
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